Research programme: IRAK1/4 inhibitors - Kurome Therapeutics

Alternative Names: KME-yyyy

Latest Information Update: 05 Oct 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kurome Therapeutics
Class
Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors; IRAK4 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

26 Sep 2023 IRAK1/4 inhibitors are available for licensing as of 26 Sep 2023. https://www.kurometherapeutics.com/partnering/
26 Sep 2023 Early research in Immunological disorders in USA (unspecified route) (Kurome Therapeutics pipeline, September 2023)
26 Sep 2023 Early research in Unspecified in USA (unspecified route) (Kurome Therapeutics pipeline, September 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com